HI
RARE icon

Harbour Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Harbour Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
30
+28
+1,400% +$695 ﹤0.01% 4216
2026
Q1 		$42 Buy
+2
New +$45 ﹤0.01% 4587
2022
Q4 		– Sell
-58
Closed -$3K – 3094
2022
Q3 		$3K Hold
58
– – ﹤0.01% 2348
2022
Q2 		$3K Buy
+58
New +$3.57K ﹤0.01% 2348
2021
Q4 		$5K Buy
58
+21
+57% +$1.71K ﹤0.01% 2190
2021
Q3 		$3K Buy
+37
New +$3.34K ﹤0.01% 3216

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Harbour Investments's RARE Position: Q2 2026 in Review

Harbour Investments increased its Ultragenyx Pharmaceutical (RARE) stake by 1,400% in Q2 2026, buying an estimated $695 and bringing the position to 30 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #4216.

Harbour Investments first reported a position in RARE in Q3 2021 and has held it in 6 quarters since. The position peaked at $5K in Q4 2021. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Harbour Investments held 30 shares of Ultragenyx Pharmaceutical worth $1K as of Q2 2026.
  • Harbour Investments bought 28 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $695.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4216 holding.
  • Harbour Investments first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and has held it in 6 quarters since.
  • Harbour Investments's Ultragenyx Pharmaceutical position peaked at $5K in Q4 2021.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.